The Lung Microbiome in Moderate and Severe Chronic Obstructive Pulmonary Disease
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder characterized by incompletely reversible airflow obstruction. Bacterial infection of the lower respiratory tract contributes to approximately 50% of COPD exacerbations. Even during periods of stable lung function, the lung harbors a community of bacteria, termed the microbiome. The role of the lung microbiome in the pathogenesis of COPD remains unknown. The COPD lung microbiome, like the healthy lung microbiome, appears to reflect microaspiration of oral microflora. Here we describe the COPD lung microbiome of 22 patients with Moderate or Severe COPD compared to 10 healthy control patients. The composition of the lung microbiomes was determined using 454 pyrosequencing of 16S rDNA found in bronchoalveolar lavage fluid. Sequences were analyzed using mothur, Ribosomal Database Project, Fast UniFrac, and Metastats. Our results showed a significant increase in microbial diversity with the development of COPD. The main phyla in all samples were Actinobacteria, Firmicutes, and Proteobacteria. Principal coordinate analyses demonstrated separation of control and COPD samples, but samples did not cluster based on disease severity. However, samples did cluster based on the use of inhaled corticosteroids and inhaled bronchodilators. Metastats analyses demonstrated an increased abundance of several oral bacteria in COPD samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The microbiome, including the mycobiome, is largely dependent on the area of the body, and may be altered during disease (Pragman et al., 2010; Mukherjee et al., 2014; Gouba and Drancourt, 2015).”
From Iron at the Centre of Candida albicans Interactions (2018) · cites this paper as Pragman et al., 2010
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549 · cited 1×
“uchime implemented in mothur [37] were used to truncate low-quality sequences and remove chimeras, respectively.”
MethodMuyzer, G., de Waal, E. C., & Uitterlinden, A. G. (1993) · Applied and Environmental Microbiology · doi:10.1128/aem.59.3.695-700.1993 · Cited by 11,429 · cited 1×
“PCR amplification using 16S rRNA gene primers specific to the constant regions flanking the V3 region [35,36] was performed using 20 cycles.”
MethodMultiple sequence alignment with the Clustal series of programs
Chenna, R. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg500 · Cited by 4,875 · cited 1×
“For PCoA analyses, sequences were dereplicated and ClustalW was used to align the dereplicated sequences [38].”
MethodThe Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762 · cited 2×
“To minimize effects of random sequencing errors, we used RDP Pipeline [4] to eliminate (a) sequences that did not appropriately match the PCR primer and the barcode at the beginning of a read, (b) sequence reads with ,50 bases after the proximal PCR primer if they terminated before reaching the distal”
MethodDewhirst, F. E., Chen, T., Izard, J., Paster, B. J., Tanner, A. C. R., Yu, W.-H., Lakshmanan, A., & Wade, W. G. (2010) · Journal of Bacteriology · doi:10.1128/jb.00542-10 · Cited by 3,352
Disordered Microbial Communities in Asthmatic Airways
Hilty, M., Burke, C., Pedro, H., Cardenas, P., Bush, A., Bossley, C., Davies, J., Ervine, A., Poulter, L., Pachter, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008578 · Cited by 1,824 · cited 1×
“The microbiome in early childhood may play a role in the development of asthma [8], while specific components of the microbiome are associated with chronic asthma in adulthood [9].”
BackgroundImproved extraction of PCR-quality community DNA from digesta and fecal samples
Yu, Z., & Morrison, M. (2004) · BioTechniques · doi:10.2144/04365st04 · Cited by 1,664 · cited 1×
“We used a previously described protocol [33] for DNA isolation that included bead beating to lyse bacterial cells, followed by precipitation with isopropanol and digestion with RNase.”
MethodStatistical Methods for Detecting Differentially Abundant Features in Clinical Metagenomic Samples
White, J. R., Nagarajan, N., & Pop, M. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000352 · Cited by 1,586 · cited 1×
“Metastats [40] was used to detect differentially abundant taxa using taxonomic data from RDP Classifier controlling the false discovery rate at 10% for each level of the taxonomy.”
MethodMicrobiota regulates immune defense against respiratory tract influenza A virus infection
Ichinohe, T., Pang, I. K., Kumamoto, Y., Peaper, D. R., Ho, J. H., Murray, T. S., & Iwasaki, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019378108 · Cited by 1,502 · cited 1×
“showed that the mouse microbiome helps regulate the immune function necessary to respond to Influenza A virus infection [12].”
BackgroundTopographical Continuity of Bacterial Populations in the Healthy Human Respiratory Tract
Charlson, E. S., Bittinger, K., Haas, A. R., Fitzgerald, A. S., Frank, I., Yadav, A., Bushman, F. D., & Collman, R. G. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201104-0655oc · Cited by 1,144 · cited 4×
“[7] who noted that the bacteria in the BALF arise from upper respiratory tract bacteria, likely through a combination of microaspiration and bronchoscopic carryover during sampling.”
BackgroundInfluential
Cited by
Items 301–400 of 445
Moffatt, L. T., Madrzykowski, D. M., Gibson, A. L. F., Powell, H. M., Cancio, L. C., Wade, C. E., Choudhry, M. A., Kovacs, E. J., Finnerty, C. C., Majetschak, M., et al. (2020) · Journal of Burn Care & Research · doi:10.1093/jbcr/irz207 · Cited by 6
Novel Insights Into Chronic Obstructive Pulmonary Disease (COPD): An Overview
Sohal, S. S., Eapen, M. S., Shukla, S. D., Courtney, J., Mahmood, M. Q., & Walters, E. H. (2014) · EMJ Respiratory · doi:10.33590/emjrespir/10312398 · Cited by 7
Ma, N., Qi, Y.-J., Liang, X., Bai, J., Deng, J., Li, M., & He, Z. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.637246 · Cited by 6
“The inclusion criteria of patients were as follows: (1) patients were more than 50 years old and had a history of smoking or smoking exposure; (2) patients were diagnosed with acute exacerbation of COPD that requires additional treatment; (3) patients had no history of asthma, tuberculosis, cystic fibrosis, obliterati…”
BackgroundMuggeo, A., Perotin, J., Brisebarre, A., Dury, S., Dormoy, V., Launois, C., Ancel, J., Mulette, P., de Champs, C., Deslée, G., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.781797 · Cited by 6
“Moreover, contradictory studies that are using such molecular approaches reported either a decrease or an increase of the microbiota diversity (Pragman et al., 2012; Sze et al., 2015).”
BackgroundPneumonia in Patients with Chronic Obstructive Pulmonary Disease
Anzueto, A., Restrepo, M. I., & Sibila, O. (2017) · Barcelona Respiratory Network · doi:10.23866/brnrev:2017-0004 · Cited by 6
De- “bug”-ing the microbiome in lung cancer
Birla, P., & Shaikh, F. Y. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10036-4 · Cited by 7
“Similarly, in chronic obstructive lung disease (COPD), there is an increased abundance of Proteobacteria and decrease in Prevotella and Veillonella [8].”
BackgroundInfluentialYue, Y., Zhang, B., He, Z., Zheng, Y., Wang, X., & Zhang, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1323613 · Cited by 6
Microbiota in the pathogenesis of COPD and its impact on the course of the disease
Fedotov, V. D., Zhestkov, A. V., Lyamin, A. V., Zaslavskaya, M. I., Сергеевна, Д. И., & TULICHEV, A. A. (2022) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2022.3.202-212 · Cited by 5
Advancements and challenges in the management of pneumonia in elderly patients with COPD
Heraud, S. O., Anzueto, A., & Restrepo, M. I. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2422961 · Cited by 8
“Patients with moderate to advance stage COPD have a higher Proteobacteria (such as Haemophilus spp. and M. catarrhalis ) [84].”
Moore, P. J., Hoffman, K., Ahmed, S., Fletcher, J. R., Wiggen, T. D., Lucas, S. K., Arif, S. J., Gilbertsen, A. J., Kent, L. A., Fiege, J. K., et al. (2025) · mBio · doi:10.1128/mbio.01338-24 · Cited by 5
“…spp.—which are present at low densities in the healthy respiratory tract (1, 2), are both prevalent and abundant in chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), non-CF bronchiecta sis, sinusitis, ventilator-associated pneumonia, and other respiratory complications (3–8).”
O’Farrell, H. E., Shaw, J. G., Goh, F., Bowman, R., Fong, K. M., Krause, L., & Yang, I. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.10.39 · Cited by 8
“Previous studies have reported that bacterial microbiome diversity decreases with increasing COPD severity (33-35).”
BackgroundMahan, L. D., Kanade, R., Mohanka, M. R., Bollineni, S., JOERNS, J. O., Kaza, V., Torres, F., Hoz, R. M. L., & Banga, A. (2020) · Clinical Transplantation · doi:10.1111/ctr.14140 · Cited by 5
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 +
Bellato, M., Cappellato, M., Longhin, F., Vecchio, C. D., Brancaccio, G., Cattelan, A. M., Brun, P., Salaris, C., Castagliuolo, I., & Camillo, B. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-43040-x · Cited by 7
The Pulmonary Microbiome, Mechanical Ventilation, and Trauma
Smith, A. D., Zhang, Y., & Shewale, S. (2012) · Biological Systems Open Access · doi:10.4172/2329-6577.1000116 · Cited by 5
“The lung microbiome associated with COPD has been studied in individuals with varying degrees of severity including those who are considered stable and those with an acute exacerbation [23,24].”
BackgroundToraldo, D. M., Rizzo, E., & Conte, L. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02237-z · Cited by 5
“In earlier studies, the use of ICS was also associated with shifts in beta diversity (Pragman et al. 2012), and sputum bacterial load (Contoli et al.”
BackgroundDiversité physiopathologique du microbiote respiratoire
Michon, A.-L., & Marchandin, H. (2015) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(15)72820-0 · Cited by 6
Genomic and systems approaches to translational biomarker discovery in immunological diseases
MacIsaac, K. D., Wang, I., Menetski, J. P., & Roberts, C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.002 · Cited by 5
Smith, D. J. F., Teng, N. M. Y., Denneny, E., Mehta, P., Stanel, S. C., Blaikley, J., Chambers, R. C., Chaudhuri, N., Garfield, B., Garner, J. L., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00826-2024 · Cited by 5
“However, no distinct clustering of samples by diagnosis was observed, suggesting that overall microbiota profiles were broadly similar across the four cohorts. https://doi.org/10.1183/23120541.00826-2024 similarly sized cohorts [38 – 40].”
InfluentialGonzales, G., Malka, R. E., Bizios, R., Dion, G. R., & Guda, T. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1524013 · Cited by 5
“…such as chronic obstructive pulmonary disease (COPD) and asthma, revealing taxa that thrive in in fl amed microenvironments (Ramsheh et al., 2021; Wang et al., 2016; Leiten et al., 2020; Millares et al., 2015; Pragman et al., 2012; Tangedal et al., 2019; Marri et al., 2013; Morimoto et al., 2024).”
Odendaal, M.-L., Taenzer, J., de Rooij, M. M. T., Kuiling, S., Bogaert, D., Franz, E., & Smit, L. A. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-00242-9 · Cited by 4
“The respiratory microbiome plays a crucial role in maintaining respiratory health and modulating disease processes, including COPD 17,18 .”
Teirilä, L., Karvala, K., Ahonen, N., Riska, H., Pietinalho, A., Tuominen, P., Piirilä, P. L., Puustinen, A., & Wolff, H. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102624 · Cited by 4
Pragman, A. A., Isaacson, R. E., Wendt, C. H., & Reilly, C. (2015) · Journal of Computational Biology · doi:10.1089/cmb.2015.0021 · Cited by 4
“As described in Pragman et al. (2012), 142 distinct genera were present in at least 1 subject.”
BackgroundSelf-citation[The Relationship Between Oral Microbiota and Chronic Obstructive Pulmonary Disease].
Yang, H., Zhang, Z., & Wang, Z. (2023) · 四川大学学报:医学版 · doi:10.12182/20230160502 · Cited by 5
NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome
Gopalakrishnan, V., Sparklin, B., Kim, J. H., Bouquet, J., Kehl, M., Kenny, T., Morehouse, C. A., Caceres, C. S., Warrener, P., Hristova, V. A., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03113-z · Cited by 4
Uncovering the hidden villain within the human respiratory microbiome
Lee, C. K., & Bent, S. J. (2014) · Diagnosis · doi:10.1515/dx-2014-0039 · Cited by 6
“Metagenomic investigations on smokers is a growing field as there has been increasing recognition that tobacco smoking is one of the leading causes of COPD in the developed nations [65].”
BackgroundInfluentialThe Microbiome at Other Mucosal Sites
Cárdenas, P., & Cookson, W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-415847-4.00006-9 · Cited by 4
Immunopathogenesis of Aspergillosis
Singh, S., Kanaujia, R., & Rudramurthy, S. M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.98782 · Cited by 5
Порушення мікробіоти дихальних шляхів у дітей з респіраторними захворюваннями (літературний огляд)
Koreniuk, O. S. (2018) · CHILD`S HEALTH · doi:10.22141/2224-0551.13.5.2018.141569 · Cited by 5
Another piece in the ‘research mosaic’ that describes the role of the lung microbiome in COPD
Huffnagle, G. B. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207415 · Cited by 4
van Moorsel, C. H. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.02002-2017 · Cited by 4
Wang, K.-S., Tu, J., Wang, Q.-X., Zhou, S., Wu, J.-R., & Qiu, Q. (2025) · Brazilian Journal of Otorhinolaryngology · doi:10.1016/j.bjorl.2025.101698 · Cited by 4
“37 Yibo Liang found that individuals with eosinophilic Chronic Rhinosinusitis with Nasal Polyps (eCRSwNPs) exhibited a markedly higher abundance of Proteobacteria at the phylum level compared to healthy controls.”
Lung microbiome dynamics in health and lung cancer
Kanteres, T., Angelakopoulou, I. M., Angelakopoulou, E. A., Tsolaki, F., Tagarakis, G. I., Manika, Κ., Exindari, M., & Gioula, G. (2025) · Microbial Genomics · doi:10.1099/mgen.0.001509 · Cited by 5
“…or relative abundance, commonly referred to as dysbiosis, have been implicated in the initiation and/or progression of various respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, pneumonia, pulmonary fibrosis and cystic fibrosis [20, 26–30].”
Taherkhani, H., KavianFar, A., Lanjanian, H., Hosseinkhan, N., Salimi, M., Nematzadeh, S., Naghizadeh, M. M., Jamalkandi, S. A., & Masoudi‐Nejad, A. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42944 · Cited by 3
Wexler, H. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397169-2.00048-2 · Cited by 4
Why is it worth remembering the lung microbiome in ICU patients?
Siwicka-Gieroba, D., Barud, M., & Dąbrowski, W. (2021) · Anaesthesiology Intensive Therapy · doi:10.5114/ait.2021.108646 · Cited by 3
“without prior diseases [9, 71, 72] (Figure 3).”
Microbial Diversity and Abundance in Pulmonary Tissue of Patients with Early-Stage Lung Cancer
Shouhua, Z., & Meilan, L. (2023) · Jundishapur Journal of Microbiology · doi:10.5812/jjm-137478 · Cited by 4
“Previous studies have shown a correlation between microbial communities and benign lung diseases such as asthma (3), chronic obstructive pulmonary disease (4), and pulmonary cystic fibrosis (5).”
BackgroundCurrent status of microbiome research in asthma and chronic obstructive pulmonary disease
Kim, B., Rhee, C. K., Jung, J. Y., Kang, H., & Cho, S. (2016) · Allergy Asthma & Respiratory Disease · doi:10.4168/aard.2016.4.5.321 · Cited by 3
Lung Microbiota and Its Impact on the Mucosal Immune Phenotype
Wu, B. G., & Segal, L. N. (2018) · ASM Press eBooks · doi:10.1128/9781555819705.ch7 · Cited by 3
LDMD: A database of microbes in human lung disease
Xu, L., Yang, J., Liang, W., Chen, J., Sun, Z., Zhang, Q., Liu, X., Qiao, F., & Li, J. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1085079 · Cited by 3
Microbiome therapeutics in respiratory illnesses
Yadav, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99336-4.00005-7 · Cited by 3
Flahaut, M., Leprohon, P., Pham, N.-P., Gingras, H., Bourbeau, J., Papadopoulou, B., Maltais, F., & Ouellette, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-43821-4 · Cited by 2
Belheouane, M., Kalsdorf, B., Niemann, S., Gaede, K. I., Lange, C. G., Heyckendorf, J., & Merker, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325362 · Cited by 2
“Moreover, numerous further studies reported an increase of Serratia in active disease phases of infectious, and non-infectious disorders in BALF specimens [24–30], and lung biopsies [31].”
Schroeder, T., Kruse, J. M., Marcy, F., Piper, S. K., Storm, C., & Nee, J. (2021) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.05.012 · Cited by 2
Gut Microbiota:Metabolic Programmers as a Lead for Deciphering Ayurvedic Pharmacokinetics
Ranade, A. V., Gayakwad, S., Chougule, S., Shirolkar, A. R., Gaidhani, S. N., & Pawar, S. D. (2020) · Current Science · doi:10.18520/cs/v119/i3/451-461 · Cited by 4
Microbiome in Inflammatory Lung Diseases: Challenges and Future Prospects
Verma, N., Thapa, K., & Dua, K. (2022) · Springer eBooks · doi:10.1007/978-981-16-8957-4_19 · Cited by 3
Haemophilus, Antibiotic Therapy and the Airway Microbiome in Chronic Obstructive PulmonarydiseasePreprint
Brill, S., James, P. L., Cuthbertson, L., Zhu, A., Lawley, T. D., Cookson, W., Cox, M. J., Wedzicha, J. A., & Moffatt, M. F. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/419127 · Cited by 2
“While studies published previously are too small to infer patterns individually, detailed profiles of the sputum microbiota of 92 clinically stable COPD patients have been reported across six studies (18-23).”
Multi-omics in Study of Lung Microbiome
Roy, D., Roy, P., & Saha, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-1844-3_12 · Cited by 2
Insights into human respiratory microbiome under dysbiosis and its analysis tool
Helal, M., & Bari, V. K. (2025) · Frontiers in Microbiomes · doi:10.3389/frmbi.2025.1549166 · Cited by 2
“Numerous studies have demonstrated that there is the enrichment of Gammaproteobacteria including Moraxella and Haemophilus genera, in moderate to advanced stages of COPD (Pragman et al., 2012; Sze et al., 2012) and also with the COPD disease progression, P. aeruginosa has been found to become more prevalent (Beasley e…”
InfluentialAirway microbial and metabolic features associated with ICS therapy in COPD
Chen, L., Yang, M., Wang, Q., Tang, Y., Yu, H., Luo, X., Du, X., & Hu, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1714879 · Cited by 1
In vivo lung microbiome alterations from burn pit emissions and/or sand inhalation exposures
Frey, J. S., Grogg, M. W., Hoisington, A. J., Wong, B. A., Mumy, K. L., & Mauzy, C. A. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1693310 · Cited by 1
Liu, K., Xie, X., Li, Y., Zhang, S., Zang, W., Li, Q., & Pan, Y. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014158 · Cited by 2
Wang, Y., Huang, Z., Zheng, J., Xu, O., Hong, Y., Ye, X., & He, Y. O. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1771765 · Cited by 1
Characteristics of Respiratory Microbiome in COPD—A Literature Review
Ciesielska-Markowska, I., Mycroft, K., Korczyński, P., Pulik, K., & Górska, K. (2026) · Advances in respiratory medicine · doi:10.3390/arm94030037 · Cited by 1
“Studies are not consistent on alpha diversity of lung microbiome in COPD patients, with some reporting decreased alpha diversity when compared to healthy individuals [25,32] while others found no significant differences [29,64].”
Microbiome Therapeutics in Respiratory Illnesses
Shariff, M., & Aditi (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00002-4 · Cited by 1
Agin, K., Hadi, M. E., & Mostafazadeh, B. (2014) · International Journal of Medical Toxicology and Forensic Medicine · doi:10.22037/ijmtfm.v4i3(summer).5818 · Cited by 1
“Susceptibility to microbial infection in the lung (microbiome) increased chronic inflammation and has even seen in the COPD patient in the stable condition (36).”
BackgroundInfections in the nose and exacerbations of chronic respiratory disorders
Xepapadaki, P. V., Megremis, S., Kitsioulis, N. A., & Papadopoulos, N. G. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10009916 · Cited by 3
The Respiratory Microbiome in COPD
O’Carroll, O., Peart, J., Mullen, E., & Burke, C. M. (2018) · InTech eBooks · doi:10.5772/intechopen.70776 · Cited by 1
“This is particularly true of COPD lungs where very significant temporal and biogeographical variations in diversity and abundance have been seen [32].”
BackgroundThe Microbiome Associated with Lung Cancer
Tsay, J.-C. J., Murthy, V., & Segal, L. N. (2019) · Current cancer research · doi:10.1007/978-3-030-04155-7_8 · Cited by 1
Baranova, E. D., & Druzhinin, V. G. (2019) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416819020022 · Cited by 1
Randerath, W. J., Dreher, M., Gompelmann, D., Held, M., Koczulla, A. R., Köhnlein, T., Rohde, G. G. U., Wälscher, J., Watz, H., & Steinkamp, G. (2020) · Pneumologie · doi:10.1055/a-1186-7333 · Cited by 2
“Mit dem Schweregrad der COPD korreliert das Mikrobiom nicht [38].”
BackgroundPortezan, C. N., & Capel, L. M. M. (2021) · Brazilian Journal of Development · doi:10.34117/bjdv7n8-597 · Cited by 1
Role of probiotics in the management of respiratory infections
Méndez-Malagón, C., Egea-Zorrilla, A., Pérez-Ferrer, P. A., & Plaza‐Díaz, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823733-5.00030-1 · Cited by 1
Starkel, J. L., Stapke, C., Stanley-O’Malley, A., & Noland, D. (2020) · Springer eBooks · doi:10.1007/978-3-030-30730-1_51 · Cited by 1
Russo, E., Curini, L., Fabbrizzi, A., & Amedei, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-8957-4_14 · Cited by 1
Interplay of Microbiome, Inflammation, and Immunity in Inflammatory Lung Diseases
Malhotra, H., Kamboj, A., Kaushik, P., & Gautam, R. K. (2022) · Springer eBooks · doi:10.1007/978-981-16-8957-4_4 · Cited by 1
Druzhinin, V. G., Baranova, E. D., Сергеевич, Д. П., Matskova, L. V., Paradnikova, S. A., Volobaev, V. P., & Larionov, A. V. (2022) · Ecological genetics · doi:10.17816/ecogen108807 · Cited by 1
Chronic Cavitary Pulmonary Histoplasmosis–Novel Concepts Regarding Pathogenesis
Fisher, J. F., Saccente, M., Deepe, G. S., Savage, N. M., Askar, W., & Vázquez, J. A. (2025) · Journal of Fungi · doi:10.3390/jof11030201 · Cited by 1
“Certain taxonomic groups of pro-inflammatory bacteria, such as Klebsiella pneumoniae and Pseudomonas aeruginosa , are often part of the microbiota of these persons; on occasion, even Pneumocystis jirovecii has been isolated [32–34].”
Baranova, E. D., & Druzhinin, V. G. (2019) · Molecular Genetics Microbiology and Virology (Russian) · doi:10.17116/molgen20193702158 · Cited by 1
Bernard, L. (2020) · theses.fr (ABES) · doi:10.70675/589a776dz18d9z4813z9d6fzd73632aa4df7 · Cited by 1
New Aspects of Alveolar Adaptive Immune Responses in COPD
Mori, M. (2013) · Lund University Publications (Lund University)
Purcell, P. (2013) · Northumbria Research Link (Northumbria University)
Charting human microbiome and metabolome changes in disease and stress
Cameron, S. J. S. (2015)
Mechanically Ventilated Patients with Suspected Pneumonia
Toma, I., Siegel, M., Keiser, J. F., Yakovleva, A., Kim, A., Davenport, L., Devaney, J., Hoffman, E. P., Alsubail, R., Crandall, K. A., et al. (2014)
Smith, A. D. (2015) · Digital Commons @ UNT Health Science Center · Cited by 2
Prevalence and load of airway bacteria in chronic obstructive pulmonary disease
Garcha, D. S. (2014) · UCL Discovery (University College London)
The Airway Microbiome After Burn and Inhalation Injury
Walsh, D. M. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/f013-s169
The Effect of Agricultural Exposures and Genetics on Respiratory Phenotypes
Boyd, L. W.-M. (2016) · DigitalCommons@UNMC
Quantitative Inferences from the Lung Microbiome
Tipton, L. (2017) · D-Scholarship@Pitt (University of Pittsburgh)
Genetic and environmental influences on the development of allergic pulmonary disease
Sherburn, R. T. (2015) · doi:10.25560/46042
“Investigation of the human microbiota in chronic obstructive pulmonary disease (COPD) patients have described the lung microbiomealtering effect of inhaled steroids (Pragman et al., 2012).”
BackgroundKarnaushkina, M. A., Fedosenko, S. V., Сазонов, А. Э., Петров, В. А., Ovsyannikov, D. Y., & Ogorodova, L. M. (2018) · Современные технологии в медицине · doi:10.17691/stm2018.10.2.11
The lung microbiome in obstructive airways disease: potential pathogenetic roles
Chung, K. F., Huffnagle, G. B., & Huang, Y. J. (2019) · European Respiratory Society eBooks · doi:10.1183/2312508x.10016118 · Cited by 1
Chishimba, L. (2016) · Research Explorer (The University of Manchester)
Moleres, J. (2018) · Academica-e (Universidad Pública de Navarra)
Ye, M., Zhou, J., Wu, S., Xia, J., Wei, S., Song, Y., Tong, L., Zhang, X., & Xu, N. (2020) · Research Square · doi:10.21203/rs.3.rs-115310/v1
The Role of the Microbiome-Gut-Brain Axis in Schizophrenia and Clozapine-Induced Weight Gain
Liu, J., Palma, G. D., Gorbovskaya, I., Hahn, M., Verdu, E. F., Berčík, P., & Müller, D. J. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.02.854 · Cited by 1
Rogers, G. B. (2018) · European Respiratory Society eBooks · doi:10.1183/2312508x.10015617
Tiew, P. Y. (2020) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/145518
Kolla, H. B., Reddy, P. N., & Bramhachari, P. V. (2021) · Springer eBooks · doi:10.1007/978-981-16-3156-6_7
The Rest Is Noise: Finding Signals in Lung Microbiome Data Analysis
Boix-Amorós, A., Lee, A., & Clemente, J. C. (2022) · Respiratory medicine · doi:10.1007/978-3-030-87104-8_3
Sulaiman, I., Tsay, J.-C. J., & Segal, L. N. (2022) · Respiratory medicine · doi:10.1007/978-3-030-87104-8_8
The Respiratory Microbiome in Health and Disease
Invernizzi, R., & Molyneaux, P. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00196-7
Bacterial Colonization in COPD
Donnelly, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00242-0
Yadav, M., & Bhambi, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00078-4
Scharte, J. M. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8911
Chronic Respiratory Disease, COPD
Huang, Y. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6418-1_698-1
Chronic Respiratory Disease, COPD
Huang, Y. J. (2015) · Springer eBooks · doi:10.1007/978-1-4899-7475-4_698
García-Núñez, M., Millares, L., Pomares, X., Ferrari, R. G., Pérez‐Brocal, V., Gallego, M., Espasa, M., Moyá, A., & Monsó, E. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.03358-14
“(2) is not well established yet, and further research in this field is needed.”
BackgroundLee, H. J., Jin, K. N., Lee, H. W., Lee, J., Park, T. Y., Heo, E. Y., & Kim, D. K. (2022) · International Journal of COPD · doi:10.2147/copd.s372735
“For example, the prolonged presence of slowly dissolving particles of fluticasone propionate in the airway epithelial lining fluid compared to budesonide may cause protracted local immunosuppression.(12,13) Moreover, phagocytosis of lipophilic ICS particles by airway/alveolar macrophages might lead to impaired macroph…”
Background
Metadata
- Authors
- Pragman, A. A., Kim, H. B., Reilly, C. S., Wendt, C., & Isaacson, R. E.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Isaacson, Richard E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-11
- Volume
- 7
- Issue
- 10
- Pages
- e47305
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3469539
- OpenAlex
- W2077691383
- Cited by
- 437
- References
- 42
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 29 · 2023: 20 · 2022: 37 · 2021: 50 · 2020: 39 · 2019: 26 · 2018: 38 · 2017: 34 · 2016: 37 · 2015: 28 · 2014: 39 · 2013: 20 · 2012: 2
- FWCI
- 22.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- University of Minnesota
- Forskningsrådet om Hälsa, Arbetsliv och Välfärd
- National Institutes of Health (n01hr096140-001)
- University of Illinois at Urbana-Champaign
- National Heart, Lung, and Blood Institute (N01 HR096140, N010HR-96140)
- National Institute of Allergy and Infectious Diseases (T32AI55433, T32AI055433)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- lung microbiome, chronic obstructive pulmonary disease, COPD exacerbations, bronchoalveolar lavage fluid, microbial diversity, oral bacteria, inhaled corticosteroids, inhaled bronchodilators, disease severity, actinobacteria, Firmicutes, Proteobacteria
- MeSH terms
- Adult, Aged, Bronchoalveolar Lavage Fluid, Chronic Disease, Female, Humans, Lung, Male, Middle Aged, RNA, Ribosomal, 16S, Proteobacteria, Pulmonary Disease, Chronic Obstructive, Actinobacteria, Bacteroidetes, Fusobacteria, Metagenome, Acidobacteria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.